This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (283)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Topic Collections  • Revascularization  • Cardiovascular System  • Surgery  • Surgical Interventions  • Cardiovascular/ Cardiothoracic Surgery  • Randomized Controlled Trial  • Cardiovascular Intervention  • Alert me on articles by topic  Social Bookmarking   What's this?

A Randomized Controlled Trial

Patrick W. J. C. Serruys, MD,PhD; Pim de Feyter, MD; Carlos Macaya, MD; Norbert Kokott, MD; Jacques Puel, MD; Matthias Vrolix, MD; Angelo Branzi, MD; Marcelo C. Bertolami, MD; Graham Jackson, MD; Bradley Strauss, MD; Bernhard Meier, MD; for the Lescol Intervention Prevention Study (LIPS) Investigators

JAMA. 2002;287:3215-3222.

Context  Percutaneous coronary intervention (PCI) is associated with excellent short-term improvements in ischemic symptoms, yet only three fifths of PCI patients at 5 years and one third of patients at 10 years remain free of major adverse cardiac events (MACE).

Objective  To determine whether treatment with fluvastatin reduces MACE in patients who have undergone PCI.

Design and Setting  Randomized, double-blind, placebo-controlled trial conducted at 77 referral centers in Europe, Canada, and Brazil.

Patients  A total of 1677 patients (aged 18-80 years) recruited between April 1996 and October 1998 with stable or unstable angina or silent ischemia following successful completion of their first PCI who had baseline total cholesterol levels between 135 and 270 mg/dL (3.5-7.0 mmol/L), with fasting triglyceride levels of less than 400 mg/dL (4.5 mmol/L).

Interventions  Patients were randomly assigned to receive treatment with fluvastatin, 80 mg/d (n = 844), or matching placebo (n = 833) at hospital discharge for 3 to 4 years.

Main Outcome Measure  Survival time free of MACE, defined as cardiac death, nonfatal myocardial infarction, or reintervention procedure, compared between the treatment and placebo groups.

Results  Median time between PCI and first dose of study medication was 2.0 days, and median follow-up was 3.9 years. MACE-free survival time was significantly longer in the fluvastatin group (P = .01). One hundred eighty-one (21.4%) of 844 patients in the fluvastatin group and 222 (26.7%) of 833 patients in the placebo group had at least 1 MACE (relative risk [RR], 0.78; 95% confidence interval [CI], 0.64-0.95; P = .01). This result was independent of baseline total cholesterol levels (above [RR, 0.76; 95% CI, 0.56-1.04] vs below [RR, 0.77; 95% CI, 0.57-1.02] the median). In subgroup analysis, the risk of MACE was reduced in patients with diabetes (n = 202; RR, 0.53; 95% CI, 0.29-0.97; P = .04) and in those with multivessel disease (n = 614; RR, 0.66; 95% CI, 0.48-0.91; P = .01) who received fluvastatin compared with those who received placebo. There were no instances of creatine phosphokinase elevations 10 or more times the upper limit of normal or rhabdomyolysis in the fluvastatin group.

Conclusion  Fluvastatin treatment in patients with average cholesterol levels undergoing their first successful PCI significantly reduces the risk of major adverse cardiac events.

Author Affiliations: Interventional Cardiology, Thoraxcenter, Academic Hospital, Rotterdam, the Netherlands (Drs Serruys and de Feyter); Cardiology Department, Hospital San Carlos, Madrid, Spain (Dr Macaya); Cardiology Department, Hopital Purpan, Toulouse, France (Dr Puel); Cardiology Department, St Jan Hospital, Genk, Belgium (Dr Vrolix); Cardiology Department, Ospedale Santa Orsola, Bologna, Italy (Dr Branzi); Institute Dante Pazzanese of Cardiology, Sao Paulo, Brazil (Dr Bertolami); Cardiology Department, Guys Hospital, London, England (Dr Jackson); Division of Cardiology, St Michaels Hospital, Toronto, Ontario (Dr Strauss); Medical Department, Cardiology, University Hospital Insel, Bern, Switzerland (Dr Meier). Dr Kokott is in cardiological private practice affiliated with Koepenick Hospital, Berlin, Germany.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

RELATED ARTICLES

Preventing Cardiac Events and Restenosis After Percutaneous Coronary Intervention
George Sopko
JAMA. 2002;287(24):3259-3261.
EXTRACT | FULL TEXT  

June 26, 2002
JAMA. 2002;287(24):3313-3314.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Pravastatin for Cardiovascular Event Primary Prevention in Patients With Mild-to-Moderate Hypertension in the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study
Kushiro et al.
Hypertension 2009;53:135-141.
ABSTRACT | FULL TEXT  

JUPITER to Earth: A statin helps people with normal LDL-C and high hs-CRP, but what does it mean?
SHISHEHBOR and HAZEN
Cleveland Clinic Journal of Medicine 2009;76:37-44.
ABSTRACT | FULL TEXT  

Statins, Low-Density Lipoprotein Cholesterol, and Risk of Cancer
Alsheikh-Ali et al.
J Am Coll Cardiol 2008;52:1141-1147.
ABSTRACT | FULL TEXT  

Mortality differences between men and women after percutaneous coronary interventions. A 25-year, single-center experience.
Singh et al.
J Am Coll Cardiol 2008;51:2313-2320.
ABSTRACT | FULL TEXT  

Lipoprotein Management in Patients With Cardiometabolic Risk: Consensus Conference Report From the American Diabetes Association and the American College of Cardiology Foundation
Brunzell et al.
J Am Coll Cardiol 2008;51:1512-1524.
FULL TEXT  

Effect of Lower Targets for Blood Pressure and LDL Cholesterol on Atherosclerosis in Diabetes: The SANDS Randomized Trial
Howard et al.
JAMA 2008;299:1678-1689.
ABSTRACT | FULL TEXT  

Lipoprotein Management in Patients With Cardiometabolic Risk: Consensus statement from the American Diabetes Association and the American College of Cardiology Foundation
Brunzell et al.
Diabetes Care 2008;31:811-822.
FULL TEXT  

Statins for secondary prevention in elderly patients: a hierarchical bayesian meta-analysis.
Afilalo et al.
J Am Coll Cardiol 2008;51:37-45.
ABSTRACT | FULL TEXT  

Efficacy and Safety of Statin Monotherapy in Older Adults: A Meta-Analysis
Roberts et al.
Journals of Gerontology Series A: Biological Sciences and Medical Sciences 2007;62:879-887.
ABSTRACT | FULL TEXT  

Effect of the Magnitude of Lipid Lowering on Risk of Elevated Liver Enzymes, Rhabdomyolysis, and Cancer: Insights From Large Randomized Statin Trials
Alsheikh-Ali et al.
J Am Coll Cardiol 2007;50:409-418.
ABSTRACT | FULL TEXT  

A review of high-dose statin therapy: targeting cholesterol and inflammation in atherosclerosis
Patel et al.
Eur Heart J 2007;28:664-672.
ABSTRACT | FULL TEXT  

Effects of Statins on Restenosis After Coronary Stent Implantation
Kamishirado et al.
ANGIOLOGY 2007;58:55-60.
ABSTRACT  

The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes: Part I: Pathophysiology and Clinical Trial Evidence (Risk Factors Through Stable Coronary Artery Disease)
Dzau et al.
Circulation 2006;114:2850-2870.
FULL TEXT  

Statins and Cancer Risk: A Literature-Based Meta-Analysis and Meta-Regression Analysis of 35 Randomized Controlled Trials
Bonovas et al.
JCO 2006;24:4808-4817.
ABSTRACT | FULL TEXT  

The Effect of Early, Intensive Statin Therapy on Acute Coronary Syndrome: A Meta-analysis of Randomized Controlled Trials.
Hulten et al.
Arch Intern Med 2006;166:1814-1821.
ABSTRACT | FULL TEXT  

Management of Dyslipidemias in Patients with Diabetes and Chronic Kidney Disease
Molitch
CJASN 2006;1:1090-1099.
ABSTRACT | FULL TEXT  

Statins in the treatment of chronic heart failure: Biological and clinical considerations
van der Harst et al.
Cardiovasc Res 2006;71:443-454.
ABSTRACT | FULL TEXT  

THE GREAT DEBATE EDITORIAL, REVISITED: RESPONSE
Freedland et al.
Psychosom. Med. 2006;68:638-640.
FULL TEXT  

Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials
Costa et al.
BMJ 2006;332:1115-1124.
ABSTRACT | FULL TEXT  

Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials.
Briel et al.
JAMA 2006;295:2046-2056.
ABSTRACT | FULL TEXT  

Prevention of Positive Coronary Artery Remodeling with Statin Therapy in Patients with Coronary Artery Diseases
Suzuki et al.
ANGIOLOGY 2006;57:259-265.
ABSTRACT  

Long-term Care After Percutaneous Coronary Intervention: Focus on the Role of Antiplatelet Therapy
Stone and Aronow
Mayo Clin Proc. 2006;81:641-652.
ABSTRACT | FULL TEXT  

What's New? Guidelines and Goals
Wigle and Birtcher
Journal of Pharmacy Practice 2006;19:103-112.
ABSTRACT  

Direct Comparison of the A to Z and PROVE IT Trials: A Second Chance to Gain a First Impression
Brown
Circulation 2006;113:1382-1384.
FULL TEXT  

Additional Information
JAMA 2006;295:E1-E6.
FULL TEXT  

Fluvastatin Ameliorates Podocyte Injury in Proteinuric Rats via Modulation of Excessive Rho Signaling
Shibata et al.
J. Am. Soc. Nephrol. 2006;17:754-764.
ABSTRACT | FULL TEXT  

Medication-Attributed Adverse Effects in Placebo Groups: Implications for Assessment of Adverse Effects
Rief et al.
Arch Intern Med 2006;166:155-160.
ABSTRACT | FULL TEXT  

Statins and Cancer Risk: A Meta-analysis
Dale et al.
JAMA 2006;295:74-80.
ABSTRACT | FULL TEXT  

Peri-procedural myocardial injury: 2005 update
Herrmann
Eur Heart J 2005;26:2493-2519.
ABSTRACT | FULL TEXT  

Pleiotropic Effects of Statins: Benefit Beyond Cholesterol Reduction?: A Meta-Regression Analysis
Robinson et al.
J Am Coll Cardiol 2005;46:1855-1862.
ABSTRACT | FULL TEXT  

Application of Evidence-Based Medical Therapy Is Associated With Improved Outcomes After Percutaneous Coronary Intervention and Is a Valid Quality Indicator
Jaber et al.
J Am Coll Cardiol 2005;46:1473-1478.
ABSTRACT | FULL TEXT  

Complete myocardial revascularization: between myth and reality
Zimarino et al.
Eur Heart J 2005;26:1824-1830.
ABSTRACT | FULL TEXT  

One-year outcomes of coronary artery bypass graft surgery versus percutaneous coronary intervention with multiple stenting for multisystem disease: A meta-analysis of individual patient data from randomized clinical trials
Mercado et al.
J. Thorac. Cardiovasc. Surg. 2005;130:512-519.
ABSTRACT | FULL TEXT  

Impact of the elevation of biochemical markers of myocardial damage on long-term mortality after percutaneous coronary intervention: results of the CK-MB and PCI study
Cavallini et al.
Eur Heart J 2005;26:1494-1498.
ABSTRACT | FULL TEXT  

The statin studies: from targeting hypercholesterolaemia to targeting the high-risk patient
Ong
QJM 2005;98:599-614.
ABSTRACT | FULL TEXT  

Statins and the Risk of Colorectal Cancer
Poynter et al.
NEJM 2005;352:2184-2192.
ABSTRACT | FULL TEXT  

Beneficial effect of early initiation of lipid-lowering therapy following renal transplantation
Holdaas et al.
Nephrol Dial Transplant 2005;20:974-980.
ABSTRACT | FULL TEXT  

Effectiveness of statins for secondary prevention in elderly patients after acute myocardial infarction: an evaluation of class effect
Zhou et al.
CMAJ 2005;172:1187-1194.
ABSTRACT | FULL TEXT  

Cost-Effectiveness of Fluvastatin Following Successful First Percutaneous Coronary Intervention
Delea et al.
The Annals of Pharmacotherapy 2005;39:610-616.
ABSTRACT | FULL TEXT  

Review: Defining the role of statins in diabetes
Tuomilehto and Leiter
British Journal of Diabetes & Vascular Disease 2005;5:55-62.
ABSTRACT  

3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibitor, Fluvastatin, as a Novel Agent for Prophylaxis of Renal Cancer Metastasis
Horiguchi et al.
Clin. Cancer Res. 2004;10:8648-8655.
ABSTRACT | FULL TEXT  

Risk reduction with long-term clopidogrel following percutaneous coronary intervention
Steinhubl and Topol
Eur Heart J 2004;25:2169-2170.
FULL TEXT  

HMG-CoA reductase inhibitor attenuates experimental autoimmune myocarditis through inhibition of T cell activation
Azuma et al.
Cardiovasc Res 2004;64:412-420.
ABSTRACT | FULL TEXT  

Absence of Interaction Between Atorvastatin or Other Statins and Clopidogrel: Results From the Interaction Study
Serebruany et al.
Arch Intern Med 2004;164:2051-2057.
ABSTRACT | FULL TEXT  

Inflammation and restenosis after percutaneous coronary interventions
Toutouzas et al.
Eur Heart J 2004;25:1679-1687.
ABSTRACT | FULL TEXT  

Beneficial effects of fluvastatin following percutaneous coronary intervention in patients with unstable and stable angina: results from the Lescol intervention prevention study (LIPS)
Lee et al.
Heart 2004;90:1156-1161.
ABSTRACT | FULL TEXT  

Beyond Restenosis: Five-Year Clinical Outcomes From Second-Generation Coronary Stent Trials
Cutlip et al.
Circulation 2004;110:1226-1230.
ABSTRACT | FULL TEXT  

Treating multivessel disease in the era of coated stents: conclusion
Di Mario and Griffiths
Heart 2004;90:1003-1003.
FULL TEXT  

Randomized Trial of Atorvastatin for Reduction of Myocardial Damage During Coronary Intervention: Results From the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) Study
Pasceri et al.
Circulation 2004;110:674-678.
ABSTRACT | FULL TEXT  

Effectiveness of Statin Therapy in Adults With Coronary Heart Disease
Wilt et al.
Arch Intern Med 2004;164:1427-1436.
ABSTRACT | FULL TEXT  

A comparison of coronary artery stenting with angioplasty for isolated stenosis of the proximal left anterior descending coronary artery: five year clinical follow up
Versaci et al.
Heart 2004;90:672-675.
ABSTRACT | FULL TEXT  

Diabetes: preventing coronary heart disease in a high risk group
Feher
Heart 2004;90:iv18-iv21.
ABSTRACT | FULL TEXT  

Acute coronary syndromes and diabetes mellitus
Trichon and Roe
Diabetes and Vascular Disease Research 2004;1:23-32.
ABSTRACT  

Don't blame the stents
Vetrovec
J Am Coll Cardiol 2004;43:1355-1357.
FULL TEXT  

Lipid Control in the Management of Type 2 Diabetes Mellitus: A Clinical Practice Guideline from the American College of Physicians
Snow et al.
ANN INTERN MED 2004;140:644-649.
ABSTRACT | FULL TEXT  

Pharmacologic Lipid-Lowering Therapy in Type 2 Diabetes Mellitus: Background Paper for the American College of Physicians
Vijan and Hayward
ANN INTERN MED 2004;140:650-658.
ABSTRACT | FULL TEXT  

Clinical Trials and Lipid Guidelines for Type II Diabetes
Prisant
J Clin Pharmacol 2004;44:423-430.
ABSTRACT | FULL TEXT  

High-Intensity Statin Treatment for Coronary Heart Disease
Sacks
JAMA 2004;291:1132-1134.
FULL TEXT  

Myocardial perfusion imaging following percutaneous coronary intervention: the importance of restenosis, disease progression, and directed reintervention
Giedd and Bergmann
J Am Coll Cardiol 2004;43:328-336.
ABSTRACT | FULL TEXT  

Statins for primary prevention: strategic options to save lives and money
Shepherd
JRSM 2004;97:66-71.
FULL TEXT  

Application of Current Guidelines to the Management of Unstable Angina and Non-ST-Elevation Myocardial Infarction
Braunwald
Circulation 2003;108:III-28-37.
ABSTRACT | FULL TEXT  

Prognostic value and the changes of plasma levels of secretory type II phospholipase A2 in patients with coronary artery disease undergoing percutaneous coronary intervention
Liu et al.
Eur Heart J 2003;24:1824-1832.
ABSTRACT | FULL TEXT  

Review Article: Treatment of Unstable Angina Pectoris/Non-ST-Segment Elevation Myocardial Infarction in Elderly Patients
Aronow
Journals of Gerontology Series A: Biological Sciences and Medical Sciences 2003;58:M927-933.
ABSTRACT | FULL TEXT  

Evolving Strategies for the Prevention and Treatment of Coronary Restenosis
Dee and Samady
SEMIN CARDIOTHORAC VASC ANESTH 2003;7:281-293.
ABSTRACT  

Silent ischemia: unsafe at any time
Bergmann and Giedd
J Am Coll Cardiol 2003;42:41-44.
FULL TEXT  

Inflammation and Insulin Resistance
Bloomgarden
Diabetes Care 2003;26:1922-1926.
FULL TEXT  

Diabetes: can we stop the time bomb?
Fisher
Heart 2003;89:ii28-30.
ABSTRACT | FULL TEXT  

Relation of Inflammation and Benefit of Statins After Percutaneous Coronary Interventions
Chan et al.
Circulation 2003;107:1750-1756.
ABSTRACT | FULL TEXT  

Are Antiplatelet Effects of Clopidogrel Inhibited by Atorvastatin?: A Research Question Formulated but Not Yet Adequately Tested
Serebruany et al.
Circulation 2003;107:1568-1569.
FULL TEXT  

Risk for Myopathy With Statin Therapy in High-Risk Patients
Ballantyne et al.
Arch Intern Med 2003;163:553-564.
ABSTRACT | FULL TEXT  

ADDITIONAL ARTICLES ABSTRACTED IN ACP JOURNAL CLUB
Evid. Based Med. 2003;8:3-3.
FULL TEXT  

Niacin-ER and Lovastatin Treatment of Hypercholesterolemia and Mixed Dyslipidemia
Yim and Chong
The Annals of Pharmacotherapy 2003;37:106-115.
ABSTRACT | FULL TEXT  

Major Outcomes in Moderately Hypercholesterolemic, Hypertensive Patients Randomized to Pravastatin vs Usual Care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT)
The ALLHAT Officers and Coordinators for the ALLHA
JAMA 2002;288:2998-3007.
ABSTRACT | FULL TEXT  

Cardioprotective effects of an early invasive strategy for non-ST-segment elevationacute coronary syndromes: Are we all becoming "interventional" cardiologists?
Yarlagadda and Boden
J Am Coll Cardiol 2002;40:1915-1918.
FULL TEXT  

ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: A report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina)
Braunwald et al.
J Am Coll Cardiol 2002;40:1366-1374.
FULL TEXT  

ACC/AHA Guideline Update for the Management of Patients With Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction--2002: Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina)
Braunwald et al.
Circulation 2002;106:1893-1900.
FULL TEXT  

JournalScan
Malik
Heart 2002;88:319-320.
FULL TEXT  

Lipid Lowering Improves Post-PCI Outcomes
Journal Watch Cardiology 2002;2002:1-1.
FULL TEXT  

Preventing Cardiac Events and Restenosis After Percutaneous Coronary Intervention
Sopko
JAMA 2002;287:3259-3261.
FULL TEXT